谷歌浏览器插件
订阅小程序
在清言上使用

418P Two-year Follow-Up Data on the Efficacy and Safety of KN026, a HER2-targeted Bispecific Antibody Combined with Docetaxel As First-Line Treatment for HER2-positive Recurrent/metastatic Breast Cancer

Annals of Oncology(2023)

引用 0|浏览15
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要